EIKEN CHEMICAL CO., LTD.

Financial Results for Q1 FY2026

(April 1, 2026 to June 30, 2026)

EIKEN CHEMICAL CO., LTD. (Code: 4549)

July 30, 2026

* FY2026; April 1, 2026 to March 31, 2027

Executive Summary

External Environment

- ✓ Impact of rising global resource prices, geopolitical risks, U.S. trade policies, and monetary policies in major economies.
- ✓ Continued increases in logistics and raw material procurement costs driven by yen depreciation and higher crude oil prices.

Business Performance

- ✓ Sales increased on strong sales of overseas FIT reagents, tuberculosis testing reagents for developing countries, and domestic medical devices
- ✓ Profit declined due to changes in sales mix and rising raw material costs

Introduction of a Shareholder Benefit Program

Key Topics

- ✓ New Product Launch & Regulatory Approval
- ✓ Strengthening Domestic POCT Product Sales through Collaboration with TAUNS
- ✓ Inclusion in the FTSE JPX Blossom Japan Index
- ✓ Colorectal Cancer Screening Awareness Initiative Utilizing the “Unko Drill” Educational Program

Performance for Q1 FY2026

Millions of yen

	Q1 FY2025 Results	Q1 FY2026 Results	Amount of Change	Percentage of Change	FY2026 Forecast Amount	FY2026 Forecast Progress Rate (%)
Net Sales	10,197	10,728	531	5.2	42,000	25.5
Cost of Sales	6,094	6,650	556	9.1	25,650	25.9
Gross Profit	4,103	4,077	(25)	(0.6)	16,350	24.9
SG&A Expenses	3,302	3,410	107	3.3	13,280	25.7
Operating Profit	800	667	(133)	(16.7)	3,070	21.7
Ordinary Profit	813	640	(173)	(21.3)	2,900	22.1
Net Income	600	445	(154)	(25.8)	2,070	21.5
R&D Cost	973	926	(47)	(4.9)	3,600	25.7

Sales growth drivers
- Growth in FIT and Medical devices

Profit Decline Drivers
- Impact of changes in sales mix and higher raw material costs
- Increase in logistics costs and one-time expenses

Measures to achieve full-year earnings targets are already underway

- New product launches — LZ Ferritin, a latex reagent in our Profitable product group, and OC-SENSOR R70, a new analyzer for FIT, our Main product group (see p.7)
- Sales expansion through collaboration with TAUNS — expanding sales of high-margin POCT products by leveraging TAUNS' strong sales network in the clinic market.(see p.8)
- Cost reduction through logistics optimization — advancing a phased review of logistics to contain cost impacts

Sales by Segment



Millions of yen

	Q1 FY2025 Results	Q1 FY2026 Results	Amount of Change	Percentage of Change	FY2026 Forecast	
					Amount	Progress Rate (%)
Fecal immunochemical tests (FIT)	3,450	3,852	401	11.6	14,220	27.1
Immunological and serological excluding FIT	2,505	2,494	(11)	(0.4)	10,000	24.9
Urinalysis	1,187	1,075	(112)	(9.5)	4,650	23.1
Microbiological	1,081	1,050	(31)	(2.9)	4,580	22.9
Clinical chemistry test	149	143	(6)	(4.2)	640	22.4
Equipment/Food and Environment	473	451	(22)	(4.7)	1,620	27.9
Molecular test	391	449	57	14.7	1,680	26.7
Medical devices/Others	956	1,211	254	26.7	4,610	26.3
Total	10,197	10,728	531	5.2	42,000	25.5

- FIT: Strong sales growth in overseas markets, particularly Europe
- Urinalysis: Temporary decline in overseas sales
- Equip., Food & Env. : Streamlining of certain low-profit products as part of portfolio optimization
- Molecular tests: Growth in sales of TB-LAMP for overseas markets, particularly Africa
- Medical devices: Growth driven by adoption of integrated proposals combining immunoserology analyzers and other instruments

Sales by Region

Millions of yen

	Q1 FY2025 Results	Q1 FY2026 Results	Amount of Change	Percentage of Change	FY2026 Forecast	
					Amount	Progress Rate (%)
Domestic Sales	7,434	7,553	118	1.6	30,210	25.0
Overseas Sales	2,763	3,175	412	14.9	11,790	26.9
Overseas Sales Ratio	27.1%	29.6%	–	–	28.1%	–
Total	10,197	10,728	531	5.2	42,000	25.5
Americas	689	568	(120)	(17.5)	2,560	22.2
EMEA	956	1,516	559	58.5	5,160	29.4
APAC	1,117	1,090	(26)	(2.4)	4,070	26.8

■ Domestic

Growth in Medical Devices

■ Americas

Phase-out of low-margin manual FIT reagents

■ EMEA

Molecular test

・TB-LAMP sales increased in Africa

FIT

・England: Inventory build-up associated with screening program renewal

・Italy: Growth driven by a major contract win

・Spain: Growth driven by expansion of the target age group

・Norway, Denmark, and Finland: Growth driven by rising demand in each country

■ APAC

Urinalysis

Temporary sales decline

FIT

Australia: Growth driven by expansion of the target age group



▸ Americas

North America and Central & South America

▸ EMEA

Europe, Africa, the Middle East and Russia [TB-LAMP sales for developing countries are included in the EMEA region.]

▸ APAC

Asia and Oceania [All sales of urinalysis test reagents (partnership with Sysmex) overseas are included in the APAC region.]

EIKEN CHEMICAL CO., LTD.

Introduction of Shareholder Benefit Program and Related Measures

1. Introduction of Shareholder Benefit Program

With the aim of enhancing medium- to long-term corporate value by enhancing the investment appeal of the Company's stock and broadening our shareholder base, we will introduce a shareholder benefit program effective from the end-of-March 2027 record date.

Summary of the Shareholder Benefit Program (Effective from the end-of-March 2027 record date)

Measure	Eligible Shareholders	Benefit Details
Long-Term Holding Benefit	Individual shareholders who have continuously held 500 or more shares for at least three years	QUO Card Pay amount awarded based on share ownership period (3+ years: ¥2,000 / 5+ years: ¥3,000 / 10+ years: ¥5,000)

* This is scheduled to apply to shareholders registered or recorded in our register of shareholders as of March 31, 2027. For details of this program, please refer to the "Notice Regarding Introduction of Shareholder Benefits Program, etc." announced today.

Expected Effects

- ✓ To enhance the investment appeal of the Company's stock and broaden our shareholder base.
- ✓ To increase the number of long-term individual shareholders.
- ✓ Through the above two effects, we aim to achieve sustainable enhancement of our corporate value.

2. Implementation of Measures to Promote Electronic Exercise of Voting Rights

From the perspective of improving shareholder convenience and reducing our environmental impact, we will promote the electronic exercise of voting rights. The following measures will be implemented for individual shareholders who have exercised their voting rights electronically.

Summary of Measures to Promote Electronic Exercise of Voting Rights

(Effective from the 89th Ordinary General Meeting of Shareholders [AGM] scheduled for June 2027 onward)

Measure	Eligible Shareholders	Benefit Details
Promotion of Electronic Voting	Individual shareholders who exercise voting rights electronically	QUO Card Pay amount of ¥500 awarded to 500 shareholders selected by lottery

1. New Product Launch & Regulatory Approval

Immunological and serological (Latex)

Profitable product group

New Release LZ Ferritin

- Expanded Measurement Range
- Improved Reliability in the Low-Concentration Range
- Enhanced Clinical Value

Supporting Ferritin Testing from Low to High Concentrations

*Scheduled for release in Japan on July 31

FIT

Main product group

New Release OC-SENSOR R70

- High Testing Throughput
- Improved Data Stability
- Excellent Usability

Enhanced Laboratory Efficiency

*Scheduled for release in Japan, late August

Molecular test

Developing product group

Expanded Drug Coverage for MINtS

MINtS System

- Expanded Companion Drug Coverage
- Expanded Specimen Coverage

Supports treatment selection for **13** anticancer drugs

2. Strengthening Domestic POCT Product Sales through Collaboration with TAUNS

A Strategic Initiative under Management Plan 2030's "Strengthen Domestic Profitability" Strategy
Strengthening Sales Channels for the Domestic Clinic Market

Leveraging EIKEN's product strengths and TAUNS's sales network to enhance domestic profitability
Driving sustainable corporate value through contributions to healthcare and society

EIKEN CHEMICAL (Product Supply)

- Strong IVD development and manufacturing capabilities

Target Products

IMMUNO CATCH®-Adeno / IMMUNO CATCH®-Strep A
- Detects two infections from one sample
- Simple one-step operation delivers results in approx. 5 min.

×

TAUNS (Domestic Sales)

- Extensive infectious disease diagnostics sales network
- Strong access to clinics
- Leveraging existing sales channels to accelerate market penetration

Sales Launch Scheduled in Autumn 2026

Market Opportunity

Growing demand for rapid diagnostics and POCT

Earnings Contribution

Expanding sales of high-profit products

Contribution to Healthcare and Society

Contributing to timely and appropriate diagnosis in clinical settings

3. Selected as a Constituent of the FTSE JPX Blossom Japan Index

Selected for the FTSE JPX Blossom Japan Index for the second consecutive year in 2026.
Also selected for the FTSE JPX Blossom Japan Sector Relative Index for the fourth consecutive year in 2026.

2nd consecutive year

FTSE JPX Blossom Japan Index

4th consecutive year

FTSE JPX Blossom Japan Sector Relative Index

FTSE Russell confirms that EIKEN CHEMICAL CO., LTD. has been independently assessed according to the index criteria, and has satisfied the requirements to become a constituent of the FTSE JPX Blossom Japan Index. Created by the global index and data provider FTSE Russell, the FTSE JPX Blossom Japan Index is designed to measure the performance of companies demonstrating specific Environmental, Social and Governance (ESG) practices. The FTSE JPX Blossom Japan Index is used by a wide variety of market participants to create and assess responsible investment funds and other products.
The FTSE JPX Blossom Japan Sector Relative Index is designed as a sector neutral benchmark that reflects the performance of companies demonstrating specific Environmental, Social and Governance (ESG) practices in Japan.

<Reference> EIKEN and Sustainability：https://www.eiken.co.jp/en/sustainability/
ESG Data（As of July 2026）：https://www.eiken.co.jp/en/sustainability/esg_data/

4. Colorectal Cancer Screening Awareness Initiative Using the *“Unko Drill”* Educational Program

Social Impact Improving children's health literacy and promoting awareness of colorectal cancer screening.

Community Engagement Donated to elementary schools in Otawara City and Nogi Town, Tochigi Prefecture.

Screening Awareness Donated to the NPO Brave Circle for cancer screening awareness activities at municipalities nationwide.

Nationwide Outreach Available to elementary schools across Japan through the publisher's distribution network.

Issued on March 31, 2026

Donation Ceremony
in Otawara City, Tochigi Prefecture

Donation Ceremony
in Nogi Town, Tochigi Prefecture

Saving Your Health

EIKEN CHEMICAL CO., LTD.

Forward-looking Statements

- This material contains forward-looking statements about EIKEN CHEMICAL CO., LTD. (EIKEN).
- These forward-looking statements are based on the current judgments and assumptions of EIKEN in light of the information currently available to it.
- Uncertainties inherent in such judgments and assumptions, the future course of our business operations and changes in operating environments both in Japan and overseas may cause our actual results, performance, achievements, or financial position to be materially different from any future results, performance, achievements or financial position either expressed or implied within these forward-looking statements.